LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK.LN) and Prosensa said Wednesday that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968 (968), in ambulant boys with Duchenne Muscular Dystrophy or DMD.


-Commencement of this study confirms previously announced plans to progress this asset into Phase III.

-This randomized, placebo controlled study will enroll 180 patients, from up to 18 countries, and is currently the most advanced ongoing study for this rare, severely debilitating, neuromuscular disease.

-The study is designed to assess the efficacy and safety of GSK968 6 mg/kg, once weekly, compared to placebo, for 48 weeks in ambulant boys over 5 years of age with DMD The primary efficacy endpoint is a measure of muscle function using the six minute walking distance test.

-Prosensa is a privately held biopharmaceutical company.

-GlaxoSmithKline shares at 1315 GMT up 8 pence, or 0.68%, at GBP1189.50 pence, valuing the company at GBP61.81 billion.

Copyright © 2011 Dow Jones Newswires